title: Stevens-Johnson syndrome associated with glipizide therapy.
abstract: We describe a patient with Stevens-Johnson syndrome (erythema multiforme major) associated with an increase in glipizide dosage administration. Glipizide is a second-generation sulfonylurea commonly used to treat patients with noninsulin-dependent diabetes mellitus. Although several reports have documented Stevens-Johnson syndrome caused by first-generation sulfonylureas, our case appears to be the first report of a second-generation sulfonylurea associated with Stevens-Johnson syndrome.
authors.affiliation: Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, TX 52390-9069, USA.
authors.forename: Jeffrey B
authors.initials: JB
authors.lastname: Cheng
authors.forename: Robert C
authors.initials: RC
authors.lastname: Anderson
authors.forename: Ponciano D
authors.initials: PD
authors.lastname: Cruz
mesh_terms: D000328:Adult; D001707:Biopsy, Needle; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy*; D005500:Follow-Up Studies; D005913:Glipizide / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D035583:Rare Diseases; D012720:Severity of Illness Index; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000473:pathology*
chemical_list: D005913:Glipizide